Indaptus Therapeutics Company Insiders

INDP Stock  USD 2.49  0.15  5.68%   
Indaptus Therapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Indaptus Therapeutics suggests that virtually all insiders are extremely bullish. Indaptus Therapeutics employs about 7 people. The company is managed by 6 executives with a total tenure of roughly 17 years, averaging almost 2.0 years of service per executive, having 1.17 employees per reported executive.

Indaptus Therapeutics' Insider Buying Vs Selling

100

 
Selling
 
Buying

Latest Trades

2023-08-14Glen R AndersonAcquired 23934 @ 2.34View
2023-08-10Glen R AndersonAcquired 44354 @ 1.94View
Monitoring Indaptus Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Indaptus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
To learn how to invest in Indaptus Stock, please use our How to Invest in Indaptus Therapeutics guide.

Indaptus Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.5817) % which means that it has lost $0.5817 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9806) %, meaning that it created substantial loss on money invested by shareholders. Indaptus Therapeutics' management efficiency ratios could be used to measure how well Indaptus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 06/19/2024, Return On Tangible Assets is likely to drop to -1.09. In addition to that, Return On Capital Employed is likely to grow to -1.28. At this time, Indaptus Therapeutics' Total Current Liabilities is relatively stable compared to the past year. As of 06/19/2024, Liabilities And Stockholders Equity is likely to grow to about 23.5 M, while Non Current Liabilities Total is likely to drop slightly above 69.7 K.
As of 06/19/2024, Common Stock Shares Outstanding is likely to drop to about 4.8 M. In addition to that, Net Loss is likely to grow to about (12.2 M)

Indaptus Therapeutics Workforce Comparison

Indaptus Therapeutics is rated second overall in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 73.0. Indaptus Therapeutics holds roughly 7.0 in number of employees claiming about 10% of equities under Health Care industry.

Indaptus Therapeutics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Indaptus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Indaptus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Indaptus Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2022-06-01
1.0
1
1
 19,727 
 0.00 
2022-03-01
3.5
7
2
 439,350 
 20,000 
2021-09-01
0.3235
11
34
 1,031,750 
 52,874 

Indaptus Therapeutics Notable Stakeholders

An Indaptus Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Indaptus Therapeutics often face trade-offs trying to please all of them. Indaptus Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Indaptus Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Nir SassiSecretary CFOProfile
MD MBAChief OfficerProfile
Jeffrey MecklerCEO DirectorProfile
Walt EsqChief OfficerProfile
Michael NewmanChief FounderProfile
Boyan MDChief OfficerProfile

About Indaptus Therapeutics Management Performance

The success or failure of an entity such as Indaptus Therapeutics often depends on how effective the management is. Indaptus Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Indaptus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Indaptus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(1.03)(1.09)
Return On Capital Employed(1.35)(1.28)
Return On Assets(1.03)(1.09)
Return On Equity(1.28)(1.21)
The data published in Indaptus Therapeutics' official financial statements typically reflect Indaptus Therapeutics' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Indaptus Therapeutics' quantitative information. For example, before you start analyzing numbers published by Indaptus accountants, it’s essential to understand Indaptus Therapeutics' liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Please note, the imprecision that can be found in Indaptus Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Indaptus Therapeutics. Check Indaptus Therapeutics' Beneish M Score to see the likelihood of Indaptus Therapeutics' management manipulating its earnings.

Indaptus Therapeutics Workforce Analysis

Traditionally, organizations such as Indaptus Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Indaptus Therapeutics within its industry.

Indaptus Therapeutics Manpower Efficiency

Return on Indaptus Therapeutics Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee2.2M
Net Loss Per Executive2.6M
Working Capital Per Employee1.6M
Working Capital Per Executive1.9M

Additional Tools for Indaptus Stock Analysis

When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.